Brief: Insilico Medicine Receives FDA Fast Track Designation For Ism6331, The Ai-Driven Pan-Tead Inhibitor, In Advanced Mesothelioma
29/07/2026 13:31
BRIEF-Insilico Medicine Receives FDA Fast Track Designation For Ism6331, The Ai-Driven Pan-Tead Inhibitor, In Advanced Mesothelioma July 29 (Reuters) - Insilico Medicine Cayman TopCo 3696.HK:
INSILICO MEDICINE RECEIVES FDA FAST TRACK DESIGNATION FOR ISM6331, THE AI-DRIVEN PAN-TEAD INHIBITOR, IN ADVANCED MESOTHELIOMA
Source text: ID:nPn3Hn3jDa
Further company coverage: 3696.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Insilico Medicine Cayman TopCo
See all newsInSilico Medicine jumps on progress in testing of new weight-loss drug
Development Collaboration
InSilico jumps on collaboration to develop biological frontier foundation models
HK-listed InSilico Medicine climbs as chairman buys shares
Brief: Insilico Medicine Cayman Topco's Chair Purchases Aggregate 113,500 Shares In Sept 4-7